AVI BioPharma 2010 News Archive
March
February
- AVI BioPharma Receives Grants Totaling $500,000 from CureDuchenne and the Foundation to Eradicate Duchenne to Support Continuing Development of Drug Candidates to Treat Duchenne Muscular DystrophyFebruary 15, 2010, BOTHELL, WA
- AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular DystrophyFebruary 5, 2010, BOTHELL, WA
- AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of ToxicologyFebruary 4, 2010, BOTHELL, WA
January
About AVI BioPharma
RNA Platform Technology
Clinical Programs
Communication